Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis

Inclusion Criteria: * Patients willing and able to participate in the study and provide written informed consent. * Male or female. * Age ≥ 18 years at study entry. * Women of childbearing potential who use an acceptable contraceptive method (barrier, oral hormonal, injectable, subdermal), or women who are naturally postmenopausal or surgically sterile. * Clinical diagnosis of an acute episode of tendinitis, bursitis, or synovitis of the shoulder, elbow, knee, or ankle, with onset within 7 days prior to the first dose of study medication. * A score ≥ 40 mm on a 100-mm Visual Analog Scale (VAS) for maximum pain intensity during active movement, as reported by the patient at the time of study inclusion. * In the opinion of the Principal Investigator or treating physician, the participant is an appropriate candidate for treatment with the investigational product. Exclusion Criteria: * Participation in another clinical study involving an investigational treatment, or participation in such a study within 4 weeks prior to study start. * Patients whose participation could be influenced (e.g., employment relationship with the study site or sponsor, vulnerable populations, etc.). * In the investigator's medical judgment, any disease that affects prognosis and prevents outpatient management, including but not limited to: terminal cancer, renal, cardiac, respiratory, or hepatic failure, mental illness, or scheduled surgical procedures or hospitalizations. * History or presence of any…